Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 2/20 | 0.46 |
| ▸ | BACE1 | P56817 | 2/20 | 0.46 |
| ▸ | TLR7 | Q9NYK1 | 3/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | HRH1 | P35367 | 3/20 | 0.43 |
| ▸ | HRH4 | Q9H3N8 | 3/20 | 0.43 |
| ▸ | CLPP | Q16740 | 1/20 | 0.41 |
| ▸ | APP | P05067 | 1/20 | 0.41 |
| ▸ | EHMT2 | Q96KQ7 | 1/20 | 0.41 |
| ▸ | DNMT3A | Q9Y6K1 | 1/20 | 0.41 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.40 |
| ▸ | ACP1 | P24666 | 1/20 | 0.40 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2808272 | 0.91 | ACHE (0.46) | ACHEBACE1TLR7MEN1KMT2A | |
| SCHEMBL2809660 | 0.90 | ALDH1A1 (0.42) | ACHEBACE1MEN1KMT2A | |
| SCHEMBL2809433 | 0.88 | CXCR3 (0.38) | ACHEBACE1TLR7MEN1KMT2A | |
| SCHEMBL2810912 | 0.88 | ADORA3 (0.42) | ACHEBACE1MEN1KMT2AHRH1 | |
| SCHEMBL2814492 | 0.88 | TSHR (0.37) | MEN1KMT2A | |
| SCHEMBL2814133 | 0.87 | ACHE (0.43) | ACHEBACE1TLR7MEN1KMT2A | |
| SCHEMBL2809652 | 0.87 | EGFR (0.45) | MEN1KMT2A | |
| SCHEMBL2812459 | 0.86 | HRH3 (0.39) | MEN1KMT2ASIGMAR1 | |
| SCHEMBL2816723 | 0.85 | GBA1 (0.34) | ACHEBACE1TLR7HRH1HRH4 | |
| SCHEMBL2811744 | 0.85 | ACHE (0.38) | ACHEBACE1TLR7MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8343983-B2 | Substituted pyrazolo-pyrimidine compounds | ARQULE, INC. (US) | 2013-01-01 | — | — | US | disclosed |
| US-20100249110-A1 | SUBSTITUTED PYRAZOLO-PYRIMIDINE COMPOUNDS | ARQULE, INC. (US) | 2010-09-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100249110-A1 | SUBSTITUTED PYRAZOLO-PYRIMIDINE COMPOUNDS | DPYD, TYMP, TP53 | ACHE 4402/4885BACE1 3588/4885TLR7 3602/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.